title: Posttranslational changes in band 3 in adult and aging brain following treatment with ergoloid mesylates, comparison to changes observed in Alzheimer's disease.
abstract: Band 3, the most heavily used anion transport system in vertebrates, ages as cells and tissues age. Posttranslational changes in band 3 in adult and aging brain were investigated following treatment with ergoloid mesylates and compared to changes observed in Alzheimer's disease (AD). The study was conducted in a double blind fashion and was decoded only after the study was completed. The following posttranslational changes in brain band 3 occur with age: increased breakdown of band 3; decreased phosphorylation; and decreased anion transport. Autoantibodies to senescent cell antigen (SCA) synthetic peptides residue 538-554 and 812-827 increase with age, but antibodies to the former peptide are significantly reduced in ergoloid mesylate treated old mice. This is a critical transport region of band 3. Results showed the aged/altered band 3 increased in Alzheimer's disease (AD) as determined by quantitative antibody binding. Ergoloid mesylates altered the age-related posttranslational changes as follows: the observed age-related decrease in brain band 3 was partially reversed and anion transport was increased. This is consistent with the data indicating decreased autoantibodies to a critical anion transport segment of band 3. Aging appears to result in damage to a critical transport region of the anion transporter which is reflected by decreased anion transport, increased breakdown, alteration of the molecule itself, and an increase in autoantibodies to the region. Ergoloid mesylates seem to protect against this damage.
authors.affiliation: International Foundation for Biomedical Aging Research, Temple, TX 76503, USA.
authors.forename: C C
authors.initials: CC
authors.lastname: Cover
authors.forename: J E
authors.initials: JE
authors.lastname: Poulin
authors.forename: M R
authors.initials: MR
authors.lastname: Gustafson
authors.forename: T
authors.initials: T
authors.lastname: Wyant
authors.forename: D N
authors.initials: DN
authors.lastname: Gamble
authors.forename: M M
authors.initials: MM
authors.lastname: Kay
mesh_terms: D000375:Aging / Q000378:metabolism*; D000544:Alzheimer Disease / Q000378:metabolism*; D000818:Animals; D001457:Anion Exchange Protein 1, Erythrocyte / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000276:immunology / Q000378:metabolism*; D001323:Autoantibodies / Q000097:blood*; D001921:Brain / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D004311:Double-Blind Method; D004877:Ergoloid Mesylates / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D008808:Mice, Inbred CBA; D010446:Peptide Fragments / Q000276:immunology; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D012016:Reference Values; D013154:Spleen / Q000276:immunology; D013447:Sulfites / Q000378:metabolism
chemical_list: D001457:Anion Exchange Protein 1, Erythrocyte; D000943:Antigens, Differentiation; D001323:Autoantibodies; D010446:Peptide Fragments; D013447:Sulfites; C047076:senescent cell differentiation antigen; D004877:Ergoloid Mesylates